This article is from the source 'guardian' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at http://www.guardian.co.uk/business/2013/jul/29/reckitt-benckiser-strong-demand-brands
The article has changed 3 times. There is an RSS feed of changes available.
| Version 1 | Version 2 |
|---|---|
| Reckitt Benckiser upbeat as brands perform well | Reckitt Benckiser upbeat as brands perform well |
| (about 2 months later) | |
| The consumer goods group Reckitt Benckiser says it is course to achieve full-year revenue growth at the top end of expectations after strong demand for brands such as Strepsils, Durex and Nurofen. | The consumer goods group Reckitt Benckiser says it is course to achieve full-year revenue growth at the top end of expectations after strong demand for brands such as Strepsils, Durex and Nurofen. |
| The FTSE 100 company said it was pleased with the performance of its heroin substitute drug Suboxone, despite competition from generic drugmakers following the loss of patent rights. Reckitt has developed a non-tablet version of the drug, after claiming that the pill form was more likely to be accidentally taken by children. It stopped selling the tablets in the US in March. | The FTSE 100 company said it was pleased with the performance of its heroin substitute drug Suboxone, despite competition from generic drugmakers following the loss of patent rights. Reckitt has developed a non-tablet version of the drug, after claiming that the pill form was more likely to be accidentally taken by children. It stopped selling the tablets in the US in March. |
| "We have always been aware of the challenges of operating in a post-generic environment. However, we continue to see strong patient and doctor preference for film over tablets and we are very pleased that the film has maintained its volume market share of 69%," it said on Monday. | "We have always been aware of the challenges of operating in a post-generic environment. However, we continue to see strong patient and doctor preference for film over tablets and we are very pleased that the film has maintained its volume market share of 69%," it said on Monday. |
| The group, which also owns the brands Dettol and Airwick, said it was on course for full-year total revenue growth at the upper end of up to 6%. | The group, which also owns the brands Dettol and Airwick, said it was on course for full-year total revenue growth at the upper end of up to 6%. |
| Revenue in the first half rose to £5bn from £4.7bn compared with the same period a year earlier, while pre-tax profit fell to £898m from £1bn as a result of market share loss and investment in drugs development. Shares rose 1.2%. | Revenue in the first half rose to £5bn from £4.7bn compared with the same period a year earlier, while pre-tax profit fell to £898m from £1bn as a result of market share loss and investment in drugs development. Shares rose 1.2%. |
| Reckitt is focusing on its fastest growing health and hygiene business, which includes Strepsils, Dettol and Harpic. | Reckitt is focusing on its fastest growing health and hygiene business, which includes Strepsils, Dettol and Harpic. |
| It said a strong performance from its Durex condom brand was supported by "creative digital communications across the world", particularly in China, which is now the largest market for the brand in the world. | It said a strong performance from its Durex condom brand was supported by "creative digital communications across the world", particularly in China, which is now the largest market for the brand in the world. |
| Our editors' picks for the day's top news and commentary delivered to your inbox each morning. |